Method of high pressure intravesical drug delivery

Slides:



Advertisements
Similar presentations
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Advertisements

Brown JR et al. Proc ASH 2013;Abstract 523.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Preventing Medical Errors: Technical, Ethical and Social Issues J.G. Anderson, Ph.D. E.A. Balas, M.D., Ph.D. D.W. Bates, M.D. R.S. Evans, Ph.D. G.J. Kuperman,
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
How do we further reduce angina in patients already treated with a hemodynamic agent? Benefits of adding a metabolic agent to other antianginal drugs (
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Anti-inflammatory effect of meloxicam on experimental vasospasm in rat femoral artery Tayfun Hakan, M. Zafer Berkman, Turgay Ersoy, Ismail Karatas, Tangul.
Imaging Microbubbles Antony Hsu Shanti Bansal Daniel Handwerker Richard Lee Cory Piette.
Synergism : what does it mean? JW Mouton Dept Medical Microbiology Canisius Wilhelmina Hospital Nijmegen, The Netherlands.
1 Michael V. Novinski President and Chief Executive Officer November 6, 2008 Third Quarter 2008 Earnings Conference Call.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Prevention with Finasteride Ian M. Thompson, MD October, 2009.
Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.
DETRUSOR EXTERNAL SPHINCTER DYSSYNERGIA Sphincterotomy OR Stent? Saleh A.A.Binsaleh.
 Pelvic pain and dyscomfort  Frequent urination  Urge symptoms  Negative urine test  Exclusion of UTI  Presence of symptoms >3 months  Characteristic.
Predictive Models of Cancer Xenograft Models Of Childhood Solid Tumors Solid Malignancies Group St. Jude Children’s Research Hospital.
Enteric-coated alendronate sodium solid lipid nanoparticles; a novel formula to overcome barriers for the treatment of osteoporosis By Funded Project.
Evaluation of the 2 x 24hour voiding diary Sandor LOVASZ MD. PhD. Hungary, Semmelweis Medical University, Budapest ESSIC Annual Meeting Philadelphia, June.
Efficacy of sodium hyaluronate in the management of chemical and radiation cystitis Sommariva et al. Minerrva Urol Nefrol 2010.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
Cystometry. Introduction: micturition Micturition is fundamentally a spinal reflex facilitated and inhibited by higher brain centers and also subject.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
FDA’s Public Workshop: Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges Paul Goldfarb, MD, FACS.
Praxbind® - Idarucizumab
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.
The Biopharmaceutical Classification System (BCS)
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
Risk of bolus thrombolytics Shamir Mehta, MD Director, Coronary Care Unit McMaster University Medical Center Hamilton, Ontario Paul Armstrong, MD Professor.
Do IV Meds Matter in Out-of-Hospital Cardiac Arrest? Summary and Comment by John A. Marx, MD, FAAEM Published in Journal Watch Emergency Medicine December.
1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.
Correlation Between the Transdermal Permeation of Ketoprofen and its Solubility in Mixtures of a pH 6.5 Phosphate Buffer and Various Solvents Ref.: Drug.
International Neurourology Journal 2015;19: Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome Chun-Hou.
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
โดย เภสัชกรณัฐวุฒิ จรีบุญ สมโภช. OAB affects 33 million people in the United States (17% of American adults) more common in women and in older people.
Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.
International Neurourology Journal 2012;16:41-46
International Neurourology Journal 2013;17:
Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,
Vahdat L et al. Proc SABCS 2012;Abstract P
Neal B, et al. Diabetes Care 2015;38:403–411
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
The Role of Statistics in Clinical Trials
Mateos MV et al. Proc ASH 2013;Abstract 403.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) as Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)1  
Harrison CN et al. Proc ASH 2015;Abstract 59.
Senior Medical Director, Cardiovascular
Side effects of instillation and how to prevent them
The Behavior of Gases.
Sandor Lovasz MD. PhD. Rózsakert Medical Center, Budapest, Hungary
Krop I et al. SABCS 2009;Abstract 5090.
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Influence of Nerve Transsections and Combined Bladder Filling on Intravesical Electrostimulation-Induced Bladder Contraction in the Rat  Filip De Bock,
Assessment of cardiovascular function by combining clinical data with a computational model of the cardiovascular system  Koichi Sughimoto, MD, PhD, Fuyou.
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
Background: Gene Expression
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.
The American College of Cardiology Presented by Dr. Timothy Henry
Flow of Patients Through the Trial
Evaluation of the 2 x 24hour voiding diary
Flow of Patients Through Trial
Aim: How do gas molecules react to pressure, volume and temperature?
ICS TEACHING MODULE Urodynamics in children Part 2
Presentation transcript:

Method of high pressure intravesical drug delivery Sandor Lovasz MD. PhD. Dept. of Urology, Jahn Ferenc South-Pest Teaching Hospital, Budapest, Hungary

High pressure intravesical drug delivery Local, intravesical treatment - the most effective form of medical therapy in IC/PBS Reduced side effect-profile Higher concentration of the agent at bladder surface Intravesical drug is transferred by passive diffusion. Influencing factors Concentration gradient Pressure difference Time of impact Surface

High pressure intravesical drug delivery Diuresis acts confusing in intravesical therapy. Concentration reduction (dilution) Reduction of time of exposure (urination) Both parameters are adversely influenced + diuresis is highly variable and unpredictable Efforts are made to reduce influence of diures.

High pressure intravesical drug delivery Using - higher concentration - minimized diuresis - alkalized urine Mitomycin C proved to be significantly more effective in a Phase III multicenter clinical trial. Au, Badalament, Wientjes et al.: Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial Journal of the National Cancer Institute 2001

High pressure intravesical drug delivery This seems to be ideal! COSTS !!! 20-40ml filling volume of intravesical drug low intravesical pressure small bladder surface thick bladder mucosa dilution by diuresis 400-500ml filling volume of intravesical drug high intravesical pressure (50-70cmH2O) great bladder surface thin bladder mucosa no dilution by diuresis due to high pressure

High pressure intravesical drug delivery 1. Fill medication into empty bladder 2. Place special dilator balloon catheter 3. Blow up the balloon under continuous pressure control - measured inside the balloon 3. Drug is being pressed into the mucosa of the bladder

High pressure intravesical drug delivery Balloon’s characristics

High pressure intravesical drug delivery Kept continuously at max. 70cmH2O for 5-15minutes Cystometry in a wide pressure-range: Cysto-elastometry

High pressure intravesical drug delivery

High pressure intravesical drug delivery Conclusions I Intravesical drug administration combined with Simultaneous balloon dilation of the bladder provides the basically new method of High pressure intravesical drug delivery

High pressure intravesical drug delivery Conclusions II The method optimizes all parameters of passive drug diffusion concentration gradient pressure difference time of impact size of surface thickness of barrier enhances efficacy of any intravesically used drugs

High pressure intravesical drug delivery Conclusions III All optimized parameters are standardized at the same time. Undisputed advantages for basic research in the field of topical treatment of IC/PBS.

High pressure intravesical drug delivery Conclusions IV Computerized analysis of pressure-volume relation of the bladder let us measure novel physical characteristics of the bladder wall Basic volume – independent of patient’s sensitivity Distensibility – quantitative meaure of elastic properties Software freely available to anybody !

High pressure intravesical drug delivery Conclusions V Our basic goal was to establish an „open source project” for research of efficacy enhencement of topical, intravesical medical treatment (not just) for IC/PBS.

Thank you for your attention Jahn Ferenc South-Pest Teaching Hospital,    Sandor Lovasz MD. PhD. Dept. of Urology, Jahn Ferenc South-Pest Teaching Hospital, Budapest, Hungary